Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lale Tokgozoglu

Showing results (121-130 of 146) with videos related to

Pageof 15
Sort By:
Journal of Hypertension|April 11, 2018
Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatmentVasilios Kotsis, Jens Jordan, Dragan Micic, et al.
Kardiologia Polska|December 3, 2016
[2016 ESC/EAS Guidelines for the Management of Dyslipidaemias]Alberico L Catapano, Ian Graham, Guy De Backer, et al.
Atherosclerosis|June 1, 2022
The spoils of war and the long-term spoiling of health conditions of entire nationsEliano P Navarese, Klaudyna Grzelakowska, Francesco Mangini, et al.
Journal of Hypertension|April 14, 2018
Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directionsVasilios Kotsis, Konstantinos Tsioufis, Christina Antza, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology|May 24, 2017
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemiaRoberto Ferrari, Carlos Aguiar, Eduardo Alegria, et al.
JAMA Cardiology|April 30, 2020
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER TrialBrian A Bergmark, Michelle L O'Donoghue, Sabina A Murphy, et al.
Atherosclerosis. Supplements|August 29, 2015
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapyCarlos Aguiar, Eduardo Alegria, Riccardo C Bonadonna, et al.
European Heart Journal|August 28, 2016
2016 ESC/EAS Guidelines for the Management of DyslipidaemiasAlberico L Catapano, Ian Graham, Guy De Backer, et al.
Revista Espanola De Cardiologia (English Ed.)|February 2, 2018
2016 ESC/EAS Guidelines for the Management of DyslipidaemiasAlberico L Catapano, Ian Graham, Guy De Backer, et al.
European Heart Journal|September 11, 2019
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskFrançois Mach, Colin Baigent, Alberico L Catapano, et al.
Pageof 15

Showing results (121-130 of 146) with videos related to

Sort By:
Pageof 15
Journal of Hypertension|April 11, 2018
Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatmentVasilios Kotsis, Jens Jordan, Dragan Micic, et al.
Kardiologia Polska|December 3, 2016
[2016 ESC/EAS Guidelines for the Management of Dyslipidaemias]Alberico L Catapano, Ian Graham, Guy De Backer, et al.
Atherosclerosis|June 1, 2022
The spoils of war and the long-term spoiling of health conditions of entire nationsEliano P Navarese, Klaudyna Grzelakowska, Francesco Mangini, et al.
Journal of Hypertension|April 14, 2018
Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directionsVasilios Kotsis, Konstantinos Tsioufis, Christina Antza, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology|May 24, 2017
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemiaRoberto Ferrari, Carlos Aguiar, Eduardo Alegria, et al.
JAMA Cardiology|April 30, 2020
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER TrialBrian A Bergmark, Michelle L O'Donoghue, Sabina A Murphy, et al.
Atherosclerosis. Supplements|August 29, 2015
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapyCarlos Aguiar, Eduardo Alegria, Riccardo C Bonadonna, et al.
European Heart Journal|August 28, 2016
2016 ESC/EAS Guidelines for the Management of DyslipidaemiasAlberico L Catapano, Ian Graham, Guy De Backer, et al.
Revista Espanola De Cardiologia (English Ed.)|February 2, 2018
2016 ESC/EAS Guidelines for the Management of DyslipidaemiasAlberico L Catapano, Ian Graham, Guy De Backer, et al.
European Heart Journal|September 11, 2019
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskFrançois Mach, Colin Baigent, Alberico L Catapano, et al.
Pageof 15